HOME >> BIOLOGY >> NEWS
Orexigen reports positive phase II results for Excalia Combination-Therapy to treat obesity

San Diego, CA, 11:00 am EDT, October 22, 2006 OREXIGENTM Therapeutics, Inc., a privately held clinical-stage neuroscience company developing novel strategic approaches to the treatment of obesity, today announced that ExcaliaTM, a combination of two centrally-acting medications intended to provide and sustain clinically important weight loss, demonstrated significant weight loss in a six month, double-blind, phase IIa clinical study. The magnitude of weight reduction exceeded that seen with placebo. The findings showed that patients completing the blinded 24-week phase lost on average 9.2% of their weight from baseline using Excalia compared to an average of 0.4% weight loss from baseline for patients using placebo. The study results further demonstrate that weight loss continued through an additional 24 week open-label period achieving an average weight loss of 12% from baseline by 48 weeks. These top line phase IIa data for Excalia were presented at the annual meeting of the North American Association for the Study of Obesity (NAASO) in Boston.

"Excalia is designed to achieve an aggressive weight loss trajectory and then to delay the typical weight loss 'plateau' by offsetting one of the body's natural compensatory pathways. These phase II data suggest a level of efficacy that exceeded our expectations in relation to existing approaches," said Gary Tollefson, M.D., Ph.D., OREXIGEN president and CEO. "Excalia is designed to act on a specific reciprocally paired group of hypothalamic neurons that we believe will yield a clinically meaningful weight loss trajectory among significantly overweight individuals. We believe that these positive data support our theoretical approach."

Excalia is a proprietary combination of bupropion, a dopamine and norepinephrine reuptake inhibitor, plus zonisamide, an approved anticonvulsant medication. OREXIGEN's preclinical research suggests that combining these two central nervous system d
'"/>

Contact: Stephen Gendel
sgendel@biocompartners.com
212-918-4650
BioCom Partners
22-Oct-2006


Page: 1 2 3

Related biology news :

1. ChemGenex reports successful personalized dosing of Quinamed at ASCO
2. 1 month post launch, Interactive Autism Network reports 13,000 participants
3. Biosite reports on presentation of preliminary data from sepsis program
4. Biolex reports potential for more potent, efficacious antibodies in Nature Biotechnology
5. Dinosaurs climate shifted too, reports show
6. The New England Journal of Medicine reports data on eculizumab for the treatment of PNH
7. Portion distortion may contribute to expanding waistlines, study reports
8. Study reports findings on lung cancer death rates in never smokers
9. Breast implants not associated with cancer risk, study reports
10. Paper reports discovery of virus implicated in genetics of prostate cancer
11. First analysis of FDAs mifepristone adverse event reports

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/7/2020)... LOUISVILLE, Ky. (PRWEB) , ... August 06, 2020 ... ... been selected to participate in the prestigious National STEM Scholar Program, a unique ... national network building, and project support for middle school science teachers nationwide. , ...
(Date:7/31/2020)... ... July 30, 2020 , ... BioFactura, Inc. today announced ... the Joint Science & Technology Office—Chemical and Biological Defense (JSTO-CBD) of the Department ... scale-up a highly efficient mammalian cell culture-based bioprocess suitable to meet surge requirement ...
(Date:7/18/2020)... ... July 16, 2020 , ... A ... of the Invictus Medical Neoasis™ active noise control device to attenuate typical noises ... the Neoasis™ device attenuated the alarm sounds from patient monitors, ventilators and other ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... SHREWSBURY, Mass. (PRWEB) , ... July 29, 2020 ... ... clad wire that can combine up to three different materials for use with ... can combine up to three materials to meet specific design requirements, performance, and ...
(Date:7/22/2020)... ... 2020 , ... Join experts from Reed Tech , Gary Saner, Sr. ... one hour live webinar on Thursday, August 13, 2020 at 11am EDT ... medical devices. Specifically, for medical devices, the NMPA has departments dealing with medical device ...
(Date:7/10/2020)... LORTON, Va. (PRWEB) , ... July 08, 2020 ... ... laboratory testing services and products, announces a significant expansion of laboratory operations through ... robust collection for agencies implementing testing programs. , Bode-CARES provides ...
(Date:7/7/2020)... BOSTON (PRWEB) , ... July 06, 2020 , ... ... Innovative Practices Awards. Entries from Roche, Eli Lilly, Bristol-Myers Squibb, the University of ... Since 2003, Bio-IT World has hosted an elite awards program, highlighting outstanding examples ...
Breaking Biology Technology:
Cached News: